cefpodoxime

Cefpodoxime (free acid) is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis.

Cefpodoxime sodium is a third generation cephalosporin antibiotic agent. It targets gram-positive and gram-negative bacteria, especially those responsible for otitis media and pharyngitis.

Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is a

Cefpodoxime proxetil impurity B is a constituent found in Cefpodoxime proxetil, which is a third-generation cephalosporin. This compound, known as Cefpodoxime Proxetil, is a highly effective oral antibiotic with a broad spectrum of activity.

Cefpodoxime proxetil-D3 is a deuterated compound of Cefpodoxime proxetil. Cefpodoxime proxetil (T4998) has a CAS number of 87239-81-4. Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil (T4998) is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.

Cefpodoxime Proxetil EP Impurity A-D3 Sodium Salt is a deuterated compound of Cefpodoxime Proxetil EP Impurity A Sodium Salt.

Cefpodoxime-D3 Acid is a deuterated compound of Cefpodoxime Acid. Cefpodoxime Acid (T4998L) has a CAS number of 80210-62-4. Cefpodoxime (free acid) is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis.

ETX1317 is a β-lactamase inhibitor that restores the antibacterial activity of various β-lactam antibiotics, including third-generation cephalosporins like Cefpodoxime. It is applicable in bacterial infection research.

ETX0282 is an orally available, broad spectrum inhibitor of class A and C β-lactamases. Entasis is developing ETX0282 in combination with cefpodoxime proxetil, an orally available cephalosporin approved for treatment of a variety of bacterial infections.